EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Clemens Aigner
Gernot Seebacher
Gyorgy Lang
Wilfried Wisser
Walter Klepetko
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aigner, C.
Right arrow Articles by Klepetko, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aigner, C.
Right arrow Articles by Klepetko, W.
Related Collections
Right arrow Lung - transplantation

Eur J Cardiothorac Surg 2005;27:757-761
© 2005 Elsevier Science NL


Extended donor criteria for lung transplantation—a clinical reality

Clemens Aignera, Guenther Winklera, Peter Jakscha, Gernot Seebachera, Gyorgy Langb, Sharokh Taghavia, Wilfried Wissera, Walter Klepetkoa,*

a Department of Cardiothoracic Surgery, Vienna Medical University, Waehringer Guertel 18-20, 1090 Vienna, Austria
b Thoracic Surgery Clinic, Koranyi National Institute for Pulmonology, Budapest, Hungary

Received 7 September 2004; received in revised form 31 December 2004; accepted 12 January 2005.

* Corresponding author. Tel.: +43 1 40400 5644; fax: +43 1 40400 5642. (E-mail: walter.klepetko{at}meduniwien.ac.at).


    Abstract
 Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 Appendix A. Conference...
 References
 
Objective: Standard lung donor criteria have been established on opinions and individual experiences rather than on existing evidence. Since the scarcity of donor organs is one of the major limitations to lung transplantation, extension of donor lung criteria might considerably increase the donor pool. This study therefore evaluates the outcome, achieved with the use of extended donors versus standard donors and aims to redefine lung donor criteria. Methods: We performed a retrospective analysis of 98 consecutive primary lung transplantations from 94 donors from 1/2001 to 12/2002. Donors were classified as extended if they fulfilled at least one criteria: age >55 years, PaO2 at FiO2/PEEP 5 <300mmHg, tobacco history >20 pack years, inhalative drug abuse, presence of infiltration on chest X-ray or purulent secretions at bronchoscopy. Recipients were stratified in two groups according to whether they received a ‘standard’ or ‘extended’ organ. Postoperative complications, extubation time, ICU and hospital stay and survival were compared. Results: Twenty-three (24.5%) donors were extended. Twenty-six recipients (26.55%) received organs from extended donors. Differences in intubation times (12±2 days standard vs. 14±5 days extended, P=0.70), ICU stay (16±2 days standard vs. 18±5 days extended, P=0.74) and hospital stay (38±4 days standard vs. 40±6 days extended, P=0.71) were not statistically significant. Postoperative bleeding rates were comparable (n=14 standard vs. n=3 extended) as well as bronchial anastomotic complications (n=7 standard vs. n=3 extended). Three months survival was 88.89% in the standard group vs. 92.31% in the extended group. One year survival is comparable as well with 81.94 vs. 84.62%, respectively. Conclusions: The use of lung donors who fail to meet standard criteria does not impair short and medium term results compared to standard lung donors. The impact on long term development of BOS has yet to be evaluated. The strict application of standard lung donor criteria excludes a considerable number of lungs potentially suitable for transplantation, thus liberalisation of donor criteria might help to overcome donor shortage.

Key Words: Lung transplantation • Donors • Presumed consent


    1. Introduction
 Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 Appendix A. Conference...
 References
 
The quality of donor organs undisputedly has a significant impact on early and long term outcome after transplantation. Existing standard lung donor criteria have been established in an earlier period of lung transplantation based mainly on opinions and individual experiences rather than on existing evidence [1]. Since scarcity of donor organs is one of the major limitations to lung transplantation, the extension of donor lung criteria has the potential to considerably increase the donor pool. Beside the sole donor-specific criteria, re-evaluation of matching criteria might have a similar effect. Due to the constantly increasing use of marginal donor lungs, this study evaluates the outcomes achieved with the use of extended donors versus standard donors and aims to redefine lung donor criteria.


    2. Patients and methods
 Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 Appendix A. Conference...
 References
 
Ninety-eight consecutive primary lung transplantations from 94 lung donors from 1/2001 to 12/2002 were retrospectively reviewed. Donors were evaluated according to age, available medical record, blood gas analysis, available laboratory values, chest X-ray and findings during bronchoscopy and harvesting. Blood group compatibility as a prerequisite, donor/recipient matching was based primarily on size (with the predicted total donor lung capacity compared to the recipient's predicted and real total lung capacity as the primary method), age and urgency of the recipient. Additionally the estimated ischemic time was taken into account.

Donors were classified as extended if they fulfilled at least one of the following criteria: age >55 years, PaO2 at FiO2/PEEP 5 <300mmHg, tobacco history >20 pack years, inhalative drug abuse, presence of infiltration on chest X-ray or purulent secretions at bronchoscopy.

The lungs were harvested en-bloc after perfusion with a high molecular low potassium dextrane (LPD) solution and 0.5mg epoprostenol, separated at the back-table and stored separately in perfusion solution. Surgical approach for transplantation was either gained by uni- or bilateral anterolateral thoracotomy or bilateral transsternal thoracotomy (clamshell incision). If intraoperative cardiopulmonary support was required, extracorporeal membrane oxygenation (ECMO) was routinely used instead of cardiopulmonary bypass.

Recipients were stratified in two groups according to whether they received a ‘standard’ or ‘extended’ organ. Recipient diagnoses were COPD (n=33 standard group vs. n=11 extended donor group), pulmonary fibrosis (n=15 vs. 6), primary or secondary pulmonary hypertension (n=7 vs. 5), cystic fibrosis (n=13 vs. 3), bronchiectasia (n=1 vs. 1), chronic thromboembolic pulmonary hypertension and Swyer–James–Syndrom (each n=1 standard group) (Fig. 1). Mean age at transplantation was 45±16 years in the standard group compared to 45±15 years in the extended group. Gender distribution was 26 females and 46 males in the standard group compared to 20 females and six males in the extended group (P<0.01).



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1. Indications for lung transplantation.

 
Both groups were compared with regard to postoperative complications, time until extubation, ICU and hospital stay, survival and incidence of BOS.


    3. Results
 Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 Appendix A. Conference...
 References
 
Results are described as mean±SD unless otherwise indicated.

Twenty-three (24.5%) donors were extended according to the above mentioned criteria. Eight donors had a reduced arterial oxygenation, five donors were older than 55 year, in three donors pathologies on chest X-ray were detected, one donor had a smoking history of more than 20 pack-years and in one donor active cocaine abuse was known. Five donors presented with various combinations of two extended factors.

Twenty-six recipients (26.55%) received organs from extended donors. Mean waiting list time was 87±90 days in the standard group versus 101±87 days in the extended group (P=0.21). In the standard group, 58 bilateral and 14 single lung transplantations were preformed compared to 18 double and eight single in the extended group. Twenty-nine patients in the standard group and six patients in the extended group were transplanted with ECMO support. In one patient in the extended group cardiopulmonary bypass was required due to a concomitant ventricular septum defect repair. In 36 patients (27 in the standard group, nine in the extended group) ischemic time was prolonged more than 6h. Mean ischemic time was 6.1±1.0h in the standard group compared to 6.1±1.9h in the extended group (P=0.9). Additional downsizing of the donor lung due to a size mismatch was required in 10 recipients in the extended group and 17 recipients in the standard group. If matching criteria like extended graft ischemic time of more than 6h and/or size mismatch requiring downsizing of the donor lung are also taken into account then 61 (62.2%) recipients received non-guideline donor organs.

Intubation time (12±2/median 3 days standard vs. 14±5/median 4 days extended, P=0.70), intensive care unit stay (16±2/median 8 days standard vs. 18±5/median 9 days extended, P=0.74) and hospital stay (38±4/median 25 days standard vs. 40±6/median 31 days extended, P=0.71) was slightly, but not statistically significant longer in the extended group. Postoperative bleeding rates requiring operative revision were comparable in both groups (n=14 standard vs. n=3 extended, P=0.36) as well as bronchial anastomotic complications (n=7 standard (5.4% of 130 anastomoses at risk) vs. n=3 (6.8% of 44 anastomoses at risk) extended, P=0.79). Three months survival was 88.89% in the standard group vs. 92.31% in the extended group. Patient details for 30 day mortality are given in Table 1. After a mean follow up of 697+343 days (range 0–1268 days) actuarial survival is 68.35% in the standard group compared to 75.21% in the extended group (Fig. 2).


View this table:
[in this window]
[in a new window]
 
Table 1. 30 day mortality
 


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2. Kaplan–Meier survival.

 
The best lung function tests achieved after transplantation were also comparable in both groups. (FEV1% 73.5±20.8 vs. 75.1±22.8, P=0.77; TLC% 91.3±17.4 vs.99.6±19.7, P=0.10)

During the observation period, eight patients in the standard group developed bronchiolitis obliterans syndrome >0p, whereas, all of the patients in the extended group are in either BOS 0 or 0p. Mean time to onset of BOS was 223±198 days (Fig. 3).



View larger version (109K):
[in this window]
[in a new window]
 
Fig. 3. Donor chest X-ray. Partial clouding of the right hemithorax due to iatrogenic pleural fluid instillation by a misplaced subclavian catheter. Upon harvesting of the lungs the parenchyma was completely unimpaired and both lungs successfully transplanted.

 

    4. Discussion
 Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 Appendix A. Conference...
 References
 
In order to accept an organ donor, several criteria need to be taken into account (Table 2). Besides general donor criteria which might avert organ donation at all, lung specific criteria have been defined in an attempt to deduce the functional capacity of a donor lung and exclude organs likely to provide unsatisfying results. However, those criteria are based mainly on opinions and individual experiences rather than on existing evidence [1]. Several reports have been published that the use of lung donors who fail to meet all standard criteria does not significantly impair results compared to standard lung donors [2–4]. Even after refinement of guidelines [5], they still do not reflect clinical reality.


View this table:
[in this window]
[in a new window]
 
Table 2. Current standard donor lung criteria
 
Besides the sole donor criteria obviously the organisational background of a transplant program is an important factor. The Vienna lung transplant programme is established in the Austrian legal framework of ‘presumed consent’ organ donation and center orientated allocation. This results in a relatively high organ donation rate and a short waiting list with low waiting list mortality. Additionally the organ can be allocated by the center to the most suitable recipient not only by strict waiting time or size matching criteria but also according to the current medical status of the patient. Even in this setting every fourth donor accepted does not meet the standard lung donor criteria. If matching criteria like extended graft ischemic time of more than 6h and/or size mismatch requiring downsizing of the donor lung are also taken into account then 61 (62.2%) recipients received non-guideline organs. In transplant centers with long waiting lists and a high mortality rate on the waiting list, the pressure to accept marginal donor organs might be even more prevalent.

Several criteria are mentioned in the recommendations. One criterion which needs critical reflection in each individual case is the arterial oxygenation. If arterial oxygenation in an otherwise acceptable donor is reduced, potential reasons have to be scrutinized. To give an example we encountered distinct reduced arterial oxygenation in a severely obese donor. At harvesting almost total atelectasis of the lower lobe was observed, yet the lung was after full inflation completely unimpaired. Overall there is inadequate data regarding the risk/benefit ratio for the lower limit of acceptability for donor arterial blood gases [6].

The current guidelines for upper age limit suggest 55 years as maximum age. While in kidney transplantation in the framework of Eurotransplant an old-to-old program has been successfully established [7], no such efforts have been undertaken in lung transplantation. In our patients, donors up to the age of 61 have been used. A thorough evaluation of these donors, especially for malignancy and other potentially undiagnosed diseases has to be undertaken. Although smaller studies have not shown a survival disadvantage with the use of older donors [8], larger registry studies have shown a negative effect on intermediate and long term survival, particularly when combined with increased graft ischemic time [9].

Another important factor in donor evaluation is the chest X-ray. While ideally suggested, it should be clear, alterations do not necessarily preclude donation. Often basal atelectasis might mimic bilateral infiltrations. After trauma localised contusions might be present. Often judgment of the underlying cause of alteration is difficult. Yet every effort has to be made to rule out pneumonia or aspiration as source of the infiltrate. If unilateral alteration prevail, use of the contralateral side can be considered. To summarize literature, there are no adequate data to provide firm guidelines regarding utilisation of donors with abnormal chest X-rays [6].

Additionally to that, donor smoking history has to be taken into account. While recommendations suggest a donor smoking history <20 pack years, we have actually used donors with longer smoking history if no proven impairments exist. To our knowledge no reports exist reporting adverse short or long term outcome after prolonged donor smoking history.

Standard criteria also include a negative donor sputum gram stain. According to our experience this is not always readily available in donor hospitals. We only insist on this, if chest X-ray or abundant secretion at bronchoscopy suggest increased risk of colonisation. Instead we routinely perform a bacteriological swab of the donor bronchus at implantation, still providing the possibility to adapt antibiotic therapy in case of colonisation.

Beyond those purely donor-related criteria important factors are the graft ischemic time and the size matching. Current guidelines suggest an ischemic time below 6h. However, available evidence suggests few problems with extended ischemic times up to 8h, whereas an adverse interaction is noted with prolonged graft ischemic time and older donors [10]. With the use of low potassium dextrane perfusion throughout the entire observation period no adverse effect of moderate extension of ischemic time beyond 6h was noticed. Size discrepancies can be overcome by reduced size lung transplantation, including split lung transplantation, lobar transplantation or peripheral wedge resection. However, these are not considered standard procedures and not all centers perform them on a regular basis [11].

The patient numbers of this retrospective single center study are obviously too small for any meaningful all-purpose redefinition of donor lung criteria. However, they are in concordance with various other reports, suggesting that donor lung criteria can safely be expanded, yet care has to taken if multiple factors are extended and especially if extended donors are used in extended recipients. Our current center specific guidelines are summarized in Table 3. A re-evaluation of standard lung donor criteria and potentially an extension of recommended limits based on larger registry studies certainly is warranted.


View this table:
[in this window]
[in a new window]
 
Table 3. Donor lung criteria applied at Vienna lung transplant program
 
In conclusion, the use of lung donors who fail to meet standard criteria does not impair short and medium term results compared to standard lung donors in our experience. Even though the use of extended donor lungs will not fully resolve the problem of limited organ supply, the strict application of standard lung donor criteria excludes a considerable number of lungs potentially suitable for transplantation, thus liberalisation of donor criteria might help in overcoming donor shortage.


    Appendix A. Conference discussion
 Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 Appendix A. Conference...
 References
 
Dr N. van der Kaay (Rotterdam, Netherlands): Were there patients in your study which had combined donor extended criteria among them, or did they just have one extended criterion?

Dr Aigner: No, there were 5 donors who had 2 criteria extended, as I mentioned in the beginning.

Dr van der Kaay: And was there a result which was different than in the other group?

Dr Aigner: No, there was no difference in the results between the donors who had 2 extended criteria compared to those who had only 1 criterion extended.

Dr van der Kaay: Then I missed it.

Dr M. Strueber (Hannover, Germany): I have a couple of problems with the criteria used to establish the term ‘extended donor’. and this applies to both presentations.

I think it's very hard to establish a proper smoking history of a donor. Most of the time we do not know if the smoking history is more or less than 20 pack years. We just know it's a smoker or not, or heavy or not. And so this, in my opinion, is a very weak criteria.

The second is PO2: It is also a weak criterion to decide. Because in case you have a donor arterial blood gas analysis at 40%, which appear to have 130 mmHg, and then you get a bad PO2 at 100% fiO2, you don't worry anymore. But this is labeled ‘extended donor’.

And with purulent secretions, this is also a weak factor, because what is somebody calling purulent secretions and what is not? So my question is, why are you not using more standard criteria like extended ventilation time of the donor?

Dr Aigner: Well, we were referring to the ideal donor criteria mentioned in the beginning which are published by the ISHLT, as you know. And I certainly agree with you that the PO2 is a weak criterion. There are many factors why a PO2 can be decreased like, say, an obese donor who has massive basal atelectasis or there might be a malintubation or anything. But nevertheless, we needed some reference to compare and a way to define the extended donor criteria. We considered this the best way to do it according to the ISHLT criteria.

And I also agree with you that, for example, that smoking history in most cases is not exactly known. So we only classify the donors as extended if it was really known that the smoking history was definitely more than 20 pack years, which was the case in only one donor as you would have noticed.

Dr D. Van Raemdonck (Leuven, Belgium): In those donors with bad oxygenation, did you correlate the PO2 at the time of organ offer versus the PO2 during the retrieval when the lung was completely ventilated with open chest?

Dr Aigner: No, we did not do that.

Dr L. Mueller (Innsbruck, Austria): These are very important results and they also meet our results mainly. But I have two questions.

Your mean recipient age was 45 years which seems quite young. Did you analyze your results regarding the effect or the acceptability of the extended donor lungs per age group, young and older recipients? Do you have different, maybe worse results, in the older recipients?

And second question is, was it a printing mistake that you have median intubation time of 12 and 14 days?

Dr Aigner: No, the median intubation time was 4 days and 3 days. The first one was mean. There were a few recipients with very long intubation times which made up for a very long mean intubation. But the median was 4 days in the extended group and 3 days in the standard recipient group.

Dr Mueller: Okay.

Dr Aigner: And no, we did not stratify the results according to age. But the low mean age might come due to a relatively high rate of cystic fibrosis in young patients with primary pulmonary hypertension which make up the low mean age.

Dr Mueller: Do you have a feeling about the results in the older age recipient group regarding extended donors?

Dr Aigner: I think that age itself does not make so much difference. It's the stage of disease which makes more difference, whether it's a very advanced stage of disease, and it doesn't matter that much whether this is in a young CF recipient or in an old CF recipient.


    Footnotes
 
{star} Presented at the joint 18th Annual Meeting of the European Association for Cardio-thoracic Surgery and the 12th Annual Meeting of the European Society of Thoracic Surgeons, Leipzig, Germany, September 12–15, 2004.


    References
 Top
 Abstract
 1. Introduction
 2. Patients and methods
 3. Results
 4. Discussion
 Appendix A. Conference...
 References
 

  1. Patterson GA, Cooper JD. Status of lung transplantation. Surg Clin North Am 1988;68(3):545-558.[Medline]
  2. Sundaresan S, Semenkovich J, Ochoa L, Richardson G, Trulock EP, Cooper JD, Patterson GA. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 1995;109(6):1075-1079.[Abstract/Free Full Text]
  3. Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000;19(12):1199-1204.[CrossRef][Medline]
  4. Pierre AF, Sekine Y, Hutcheon MA, Waddell TK, Keshavjee SH. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg 2002;123(3):421-427.[Abstract/Free Full Text]
  5. Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH. Clinical Practice Committee, American Society of Transplantation. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001;71(9):1189-1204.[CrossRef][Medline]
  6. Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, Kotloff R, Morton J, Studer SM, Van Raemdonck D, Waddel T, Snell GI. Pulmonary Council International Society for heart and lung transplantation. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003;22(11):1183-1200.[CrossRef][Medline]
  7. Smits JM, Persijn GG, van Houwelingen HC, Claas FH, Frei U. Evaluation of the Eurotransplant Senior Program. The results of the first year. Am J Transplant 2002;2(7):664-670.[CrossRef][Medline]
  8. Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation. Chest 2000;118(5):1255-1262.[Abstract/Free Full Text]
  9. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for heart and lung transplantation: 18th Official Report-2001. J Heart Lung Transplant 2001;20(8):805-815.[CrossRef][Medline]
  10. Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999;18(5):425-431.[CrossRef][Medline]
  11. Aigner C, Mazhar S, Jaksch P, Seebacher G, Taghavi S, Marta G, Wisser W, Klepetko W. Lobar transplantation, split lung transplantation and peripheral segmental resection–reliable procedures for downsizing donor lungs. Eur J Cardiothorac Surg 2004;25(2):179-183.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
N. Shigemura, J. Bhama, D. Nguyen, J. Thacker, C. Bermudez, and Y. Toyoda
Pitfalls in donor lung procurements: how should the procedure be taught to transplant trainees?
J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 486 - 490.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
D. Van Raemdonck, A. Neyrinck, G. M. Verleden, L. Dupont, W. Coosemans, H. Decaluwe, G. Decker, P. De Leyn, P. Nafteux, and T. Lerut
Lung Donor Selection and Management
Proceedings of the ATS, January 15, 2009; 6(1): 28 - 38.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
A. Zuin, G. Marulli, M. Loy, and F. Rea
Clamshell approach for lung harvest in donor with previous aortic valve substitution
Eur. J. Cardiothorac. Surg., January 1, 2009; 35(1): 181 - 182.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Shihata, N. Ghorpade, D. Lien, and D. Modry
Ex Vivo Bilateral Pulmonary Embolectomy for Donor Lungs Prior to Transplantation
Ann. Thorac. Surg., June 1, 2008; 85(6): 2110 - 2112.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. V. Venkateswaran, V. B. Patchell, I. C. Wilson, J. G. Mascaro, R. D. Thompson, D. W. Quinn, R. A. Stockley, J. H. Coote, and R. S. Bonser
Early Donor Management Increases the Retrieval Rate of Lungs for Transplantation
Ann. Thorac. Surg., January 1, 2008; 85(1): 278 - 286.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Oto, B. J. Levvey, H. Whitford, A. P. Griffiths, T. Kotsimbos, T. J. Williams, and G. I. Snell
Feasibility and Utility of a Lung Donor Score: Correlation With Early Post-Transplant Outcomes
Ann. Thorac. Surg., January 1, 2007; 83(1): 257 - 263.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. F. Angel, D. J. Levine, M. I. Restrepo, S. Johnson, E. Sako, A. Carpenter, J. Calhoon, J. E. Cornell, S. G. Adams, G. B. Chisholm, et al.
Impact of a Lung Transplantation Donor-Management Protocol on Lung Donation and Recipient Outcomes
Am. J. Respir. Crit. Care Med., September 15, 2006; 174(6): 710 - 716.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Clemens Aigner
Gernot Seebacher
Gyorgy Lang
Wilfried Wisser
Walter Klepetko
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aigner, C.
Right arrow Articles by Klepetko, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aigner, C.
Right arrow Articles by Klepetko, W.
Related Collections
Right arrow Lung - transplantation


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS